



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Masinovsky et al.

Attorney Docket No: FHIC16963

Serial No: 08/051,455

Anticipated Classification:

Filed: April 21, 1993

Group Art Unit: 1802

Examiner: D.C. Wortman, Ph.D.

Title: IL-4 ACTS SYNERGISTICALLY WITH IL-1 β TO PROMOTE LYMPHOCYTE ADHESION TO MICROVASCULAR ENDOTHELIUM BY INDUCTION OF VCAM-1

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

May 18, 1993

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. _____ Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
2. X Copies of the listed patents, publications, and other information were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. 07/562,008, filed August 2, 1990, and relied upon for an earlier filing date under 35 U.S.C. § 120.
3. _____ A concise explanation of the relevance of document I.D. No. _____ (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided _____.
4. X Pursuant to 37 C.F.R. § 1.97(b), this information disclosure statement is being filed within three months of the filing date of the national application, within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits.



RECEIVED
MAY 26 1993
GROUP 1801

5. _____ Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:
- a. _____ a certification as specified in 37 C.F.R. § 1.97(e); or
- b. _____ the fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of \$ _____ is enclosed.
6. _____ Pursuant to 37 C.F.R. § 1.97(d) this information disclosure statement is being filed after the mailing date of either:
- a. _____ a final action under 37 C.F.R. § 1.113, or
- b. _____ a notice of allowance under 37 C.F.R. § 1.311,
- but before payment of the issue fee. The statement is accompanied by a certification as specified in 37 C.F.R. § 1.97(e), a petition requesting consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(i)(1). Check No. _____ in the amount of \$ _____ is enclosed.
7. X Please charge any additional fees or credit any overpayment to Deposit Account No. 03-1740. A duplicate copy of this request is enclosed.

Respectfully submitted,

CHRISTENSEN, O'CONNOR,
JOHNSON & KINDNESS

Thomas F. Broderick
Registration No. 31,332

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on May 18, 1993

Date: 5.18.93

TFB/jst:daf